KRAS and lung cancer: Therefore, developing non-cardiotoxic selective COX-2 inhibitors and/or agents that target the enzymes regulating PGE2 synthesis and degradation may lead to valuable chemopreventive or -therapeutic approaches for patients with mutant KRAS lung cancer.